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Impact of gender on the renal response to angiotensin II. suggesting that angiotensin II (Ang II), the effector sub-
Background. It is clear that women with renal disease progress to stance of the RAS, might be elevated in females. How-
end stage at a slower rate than do men. We hypothesized that this
ever, in nonpregnant ewes, there is a gradual, progressiveprotection may result from gender-mediated differences in responses
to angiotensin II (Ang II), which has known hemodynamic effects that rise in plasma renin activity (PRA) and circulating Ang
are thought to promote renal disease progression. We examined sex II after ovariectomy [2, 3]. Most studies in humans exam-differences in renin-angiotensin system (RAS) function by measuring
ining the relationship between gender, estrogen status,renal hemodynamic function and circulating plasma components of
the RAS at baseline and in response to graded infusions of Ang II. and the RAS have relied on the measurement of baseline
Methods. We studied two groups of normal healthy subjects, 24 men plasma concentrations of components of system. Resultsand 24 women, mean age 28 6 1 years, ingesting a controlled sodium
have been conflicting, with groups suggesting that theand protein diet. We examined baseline concentrations of angiotensin
converting enzyme, plasma renin activity, Ang II, and aldosterone. system is activated [4, 5] or blunted [6]. Few studies exist
Inulin and paraaminohippurate clearance techniques were used to that use dynamic maneuvers to examine differences inestimate effective renal plasma flow (ERPF) and glomerular filtration
RAS function between men and women. Those that haverate (GFR) at baseline and in response to graded Ang II infusion (0.5,
1.5, and 2.5 ng/kg/min). done so have provided some intriguing information. Ishi-
Results. Mean baseline values for mean arterial pressure and aldoste- bashi et al have demonstrated a significant blunting ofrone were lower in women, whereas values for plasma Ang II, GFR,
the response of PRA to sodium restriction in older hy-ERPF, and filtration fraction (FF) did not differ. In response to Ang
II, both groups exhibited a similar increase in mean arterial pressure pertensive women compared with men [7], and Magness
and a decline in ERPF. GFR was maintained during Ang II infusion et al have shown that estrogen can interfere with the vasc-only in men, resulting in an augmentation of FF. In women, GFR
ular response to Ang II, at least in pregnant women [8].declined in parallel with ERPF, and the FF response was significantly
blunted. 17b-Estradiol plasma concentrations influenced the ERPF A complete understanding of RAS function in normal
response to Ang II infusion, with higher levels predicting a blunting premenopausal women would be of interest. It is clearof the decrease. The GFR response was not affected.
that women progress to end-stage renal failure after aConclusions. The renal microcirculation in sodium-replete women
may respond differently to Ang II than that of men, with the female renal insult at a slower rate than do men [9–12], and
sex predicting a lesser augmentation of FF and possibly a blunted Ang II has both renal hemodynamic and mitogenic ef-increase in intraglomerular pressure. The mechanism remains obscure,
fects that have been implicated in renal disease progres-but these contrasting responses may help to explain gender-mediated
differences in renal disease progression. sion [13]. Therefore, we undertook a systematic analy-
sis of the baseline components of the RAS and the
renal and peripheral responsiveness to Ang II in 48 nor-
The impact of gender on the function of the renin- mal healthy men and premenopausal women, all ingest-
angiotensin system (RAS) is unclear. It is well known ing a controlled sodium and protein diet, to determine
that estrogen plays a role in the regulation of some com- whether a discernible gender difference exists. Our ratio-
ponents of the RAS. For example, a promoter region in nale reflected the possibility that the pattern of renal
the angiotensinogen gene is responsive to estrogen [1], responsiveness to Ang II might represent a physiological
and administration of exogenous estrogen raises plasma, process that could help to clarify gender-mediated differ-
hepatic, and renal concentrations of angiotensinogen, ences in disease progression.
METHODS1 See Editorial, p. 336.
SubjectsKey words: renin-angiotensin system, renal disease progression, hemo-
dynamics, Ang II, glomerular filtration rate, mean arterial pressure. Fifty normal healthy men and women were recruited
to participate in the study. Their mean age was 28 6 1Received for publication December 30, 1997
years (range 20 to 35 years). Each subject underwent aand in revised form July 29, 1998
Accepted for publication August 20, 1998 detailed history and physical examination by a qualified
internist. All were white, normotensive, nonobese, and 1999 by the International Society of Nephrology
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nonsmokers. No subject was ingesting any regular medi- utes. Subjects remained supine except to void. Blood
cations; specifically, none of the women were users of oral was collected once during each Ang II infusion period
contraceptive medications. The study was performed with for Hct, aldosterone, PRA, inulin, and PAH, and urine
the approval of the University of Toronto Human Subjects was collected for sodium, inulin, and PAH. MAP was
Review Committee and with the informed written consent also measured at the midpoint of each infusion. A further
of each subject. collection of both blood and urine was obtained at the
All subjects were counseled to adhere to a diet that end of the Ang II infusion, after a 30-minute recovery
maintained their normal caloric intake, their sodium in- period.
take to more than 200 mmol/day, and their protein intake
Sample collection and analytical methodsto 1 to 1.5 g/kg/day for seven days prior to the study. A
24-hour urine sample was obtained one day prior to the Blood samples collected for inulin and PAH determi-
study to determine urine sodium and urea excretion. nations were immediately centrifuged at 3,000 r.p.m. for
Data from subjects were not analyzed if urine sodium 10 minutes at 48C. Plasma was separated, placed on ice,
excretion was less than 180 mmol/day, resulting in the and then stored at 2708C before the assay. Inulin concen-
exclusion of two subjects, one man and one woman. trations in plasma and urine were measured by a modi-
Therefore, data from 48 subjects were analyzed. Protein fied method of Walser, Davidson and Orloff [14], and
intake was estimated from the urine urea concentration PAH concentration by a spectrophotometric method ac-
and was corrected for body weight. On the day of the cording to Brun [15]. The mean of the final two clear-
testing, the volunteer subjects reported to the Renal ance periods represents glomerular filtration rate (GFR)
Physiology Laboratory of the Toronto Hospital. All stud- and effective renal plasma flow (ERPF), expressed per
ies were conducted at 0830 hours, after an overnight fast, 1.73 m2. Filtration fraction (FF) represented the ratio of
with the subjects lying supine in a warm, quiet room. GFR to ERPF. Renal blood flow (RBF) was calculated
by dividing the ERPF by (1-Hct). Renal vascular resis-Study protocol
tance (RVR) was derived by dividing MAP by the RBF.
An 18-gauge peripheral venous cannula was inserted Serum sodium concentration was measured by an ion-
into an antecubital vein for infusions of inulin, paraami- selective electrode method, and urine sodium by a flame
nohippurate (PAH), and Ang II, and another cannula photometry method.
was placed in the opposite arm for blood sampling. Each Serum angiotensin converting enzyme (ACE) activity
subject voided and then drank sufficient water in the first was measured by a spectrophotometric method using an
45 minutes to induce a water diuresis. Approximately 200
ACE kinetic test kit (Buhlmann Laboratories AG, Scho-
ml were ingested in each hour of the protocol to maintain
nembuch, Switzerland). Briefly, serum samples and cali-an adequate urine output for collection of spontaneously
brators (20 ml) were allowed to react with a syntheticvoided samples. Hemodynamic parameters [mean arte-
peptide (N-[3-(2-furyl)acryloyl]-l-phenylalanylglycylgly-rial pressure (MAP), heart rate] were measured through-
cine) (200 ml) in a 96-well microplate. The enzyme kinet-out the study by an automated sphygmomanometer (Di-
ics at 378C were followed by the decrease in absorbancenamapp) and were recorded once in each half hour of
at 340 nm for 15 minutes with a Bio-Tek microplatethe protocol. Renal hemodynamics were measured using
reader (model # Ceres UV 900 Hdi; Bio-Tek, Burlington,inulin and PAH clearance techniques. After collecting
VT, USA).blood for inulin blank, hematocrit (Hct), Ang II, angio-
Angiotensin II was measured by radioimmunoassay.tensin converting enzyme (ACE) level, and, in the
Blood was collected into prechilled tubes containing eth-women, 17b-estradiol, and urine for inulin blank, a prim-
ylenediaminetetraacetic acid and angiotensinase inhibi-ing infusion containing 25% inulin (60 mg/kg) and 20%
tor (0.1 ml Bestatin Solution; Buhlmann Laboratories,PAH (8 mg/kg) was administered. Thereafter, inulin and
Schonembuch, Switzerland). After centrifugation, plasmaPAH were infused continuously at a rate calculated to
samples were stored at 2708C until analysis. On the daymaintain their respective plasma concentrations constant
of analysis, plasma samples were extracted on phenyl-at 20 and 1.5 mg/dl. After a 90-minute equilibration pe-
silylsilica columns. A competitive radioimmunoassay kitriod, three timed urine collections of a 20-minute dura-
supplied by Buhlmann Laboratories AG (Schonembuch,tion each were then obtained, and blood was collected
Switzerland) was used to measure the extracted Ang II.for Hct, aldosterone, and PRA.
The detection limit of the assay was approximately 2.0A solution of Ang II (2.5 mg/vial) was prepared by
pg/ml, with a precision of 8.3% intra-assay variation anddissolving the diluent in normal saline to produce a con-
9.0% interassay variation.centration of 0.5 mg/ml. Two hundred and fifty ml normal
Plasma renin activity was determined by the quantita-saline were then added to 0.2 ml Ang II to produce a
tion of angiotensin I generation by radioimmunoassayconcentration of 400 ng/ml. Ang II was infused at three
doses, 0.5, 1.5, and 2.5 ng/kg/min, each dose for 30 min- using the New England Nuclear Kit. Aldosterone was
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Table 1. Baseline characteristics Women were then divided into quartiles on the basis of
17b-estradiol plasma concentrations, and the quartilesParameter Men (N 5 24) Women (N 5 24) P value
with the highest (more than 300 pmol/liter) and the low-Age years 28 6 1 27 6 1 NS
BMI kg/m2 25 6 1 23 6 1 0.004 est (less than 100 pmol/liter) levels were compared again
MAP mm Hg 91 6 2 82 6 2 0.0008 using Wilcoxin Rank Sums and repeated measures analy-
UNaV mmol/day 220 6 17 208 6 14 NS sis of variance. All statistical analyses were performedProtein intake g/kg/day 1.15 6 0.06 1.12 6 0.04 NS
Hct 0.430 6 0.005 0.379 6 0.005 0.0001 using the statistical package SAS (SAS Institute Inc.,
Cary, NC, USA).ACE U/liter 44 6 2 48 6 2 NS
Ang II pg/ml 8 6 2 9 6 3 NS
Aldosterone pmol/liter 231 6 18 188 6 23 0.05
PRA ng Ang I/liter/min 0.17 6 0.02 0.22 6 0.07 NS RESULTS
Abbreviations are: BMI, body mass index; MAP, mean arterial pressure; Baseline characteristicsUNaV, 24-hour urine sodium excretion; protein intake, calculated from 24-hour
urine urea excretion; Hct, hematocrit; ACE, angiotensin converting enzyme; The baseline characteristics of the two groups are
Ang II, angiotensin II; PRA, plasma renin activity.
shown in Table 1. There were no significant differences in
age, 24-hour urine sodium excretion (UNaV), and serum
ACE concentrations. Although there was a significant
measured by radioimmunoassay, using the Coat-A-Count difference in urea excretion (425 6 18 mmol/day in men,
system. Plasma 17b-estradiol was determined by radio- 309 6 18 in women), calculated protein intake corrected
immunoassay using the DPC kit (Drug Products Corpo- per kg of body weight did not differ significantly. There
ration, Los Angeles, CA, USA). were significant differences in body mass index, Hct,
and MAP. Ang II levels were equivalent in the men
Statistical analysis compared with the women. PRA was numerically, but
Data were analyzed by gender and are presented not significantly, increased in women. Aldosterone levels
as mean 6 sem. Between group baseline differences were significantly lower in women compared with men.
were determined using nonparametric methods (Wil-
Renal and peripheral responses to angiotensin IIcoxin Rank Sums). Within subject and between group
examination of the responses to Ang II was by repeated As can be seen from Table 2, at baseline, women
measures analysis of variance and Bonferroni correction. exhibited a strikingly lower arterial pressure than did
Correlation coefficients were used to discern any rela- men, but no significant differences were detectable in
tionships between 17b-estradiol plasma concentrations ERPF, RBF, or FF. GFR was numerically but not sig-
nificantly increased in women compared with men. Inand the renal and humoral responses to Ang II infusion.
Table 2. Responses to angiotensin II by gender
Parameter Baseline 0.5 ng 1.5 ng 2.5 ng Recovery
Responses to Ang II in men
MAP mm Hg 92 6 1 93 6 1 96 6 2a 99 6 2a 90 6 2
GFR ml/min/1.73 m2 100 6 3 98 6 4 100 6 5 103 6 4 103 6 2
ERPF ml/min/1.73 m2 588 6 21 460 6 23a 413 6 16a 389 6 20a 590 6 38
RBF ml/min/1.73 m2 1020 6 30 790 6 32a 711 6 29a 670 6 28a 1007 6 74
FF 0.17 6 0.01 0.22 6 0.01a 0.25 6 0.01a 0.27 6 0.01a 0.18 6 0.01
RVR mm Hg/liter/min 92 6 4 126 6 5a 140 6 8a 156 6 5a 99 6 6
UNaV lmol/min 391 6 24 214 6 16a 156 6 12a 128 6 10a 259 6 26
Aldosterone pmol/liter 231 6 18 334 6 20a 442 6 24a 518 6 39a 357 6 34
PRA ng Ang I/liter/min 0.17 6 0.02 0.17 6 0.02 0.13 6 0.01 0.13 6 0.01 0.14 6 0.01
Responses to Ang II in women
MAP mm Hg 82 6 2b 83 6 2 89 6 2a 90 6 2a 80 6 2
GFR ml/min/1.73 m2 107 6 5b 95 6 5ac 93 6 5ac 95 6 5 104 6 5
ERPF ml/min/1.73 m2 586 6 31 451 6 25a 416 6 32a 390 6 26a 584 6 36
RBF ml/min/1.73 m2 945 6 50 713 6 39a 656 6 51a 609 6 43a 910 6 57
FF 0.19 6 0.01 0.21 6 0.01c 0.22 6 0.01ac 0.24 6 0.01a 0.18 6 0.01
RVR mm Hg/liter/min 92 6 7 124 6 9a 154 6 14a 163 6 13 94 6 6
UNaV lmol/min 335 6 22 184 6 15a 143 6 12a 111 6 10a 210 6 16
Aldosterone pmol/liter 188 6 23b 306 6 36a 423 6 44a 552 6 54a 359 6 36
PRA ng Ang I/liter/min 0.22 6 0.07 0.21 6 0.08 0.24 6 0.1 0.18 6 0.08 0.24 6 0.08
Abbreviations are: GFR, glomerular filtration rate (corrected per 1.73 m2); ERPF, renal plasma flow (corrected per 1.73 m2); FF, filtration fraction; RVR, renal
vascular resistance; UNaV, urinary sodium excretion; PRA, plasma renin activity.
a P , 0.05 vs. baseline value
b P , 0.05 vs. baseline value in men
c P , 0.05 vs. response to Ang II in men
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Table 3. Baseline characteristics in groups segregated
by estrogen levels
High estrogen Low estrogen
Parameter (N 5 8) (N 5 9) P value
Age years 28 6 1 27 6 1 NS
17b-estradiol pmol/liter 380 6 26 71 6 10 0.0001
BMI kg/m2 22 6 1 23 6 1 NS
UNaV mmol/day 206 6 30 210 6 24 NS
Protein intake g/kg/day 1.15 6 0.07 1.15 6 0.06 NS
Hct 0.384 6 0.01 0.379 6 0.007 NS
ACE U/liter 50 6 4 48 6 3 NS
Ang II pg/ml 12 6 4 9 6 2 NS
Aldosterone pmol/liter 252 6 37 154 6 20 0.04
PRA ng Ang I/liter/min 0.36 6 0.13 0.12 6 0.02 0.04
MAP mm Hg 84 6 2 79 6 2 0.05
GFR ml/min/1.73 m2 109 6 10 109 6 6 NS
ERPF ml/min/1.73 m2 546 6 28 630 6 49 0.05
RBF ml/min/1.73 m2 886 6 43 1018 6 80 0.04
FF 0.20 6 0.02 0.17 6 0.009 0.05
RVR mm Hg/liter/min 96 6 6 83 6 4 0.04
UNaV lmol/min 343 6 43 346 6 31 NS
Abbreviations are: BMI, body mass index; UNaV, 24-hour urine sodium excre-
tion; Hct, hematocrit; ACE, angiotensin converting enzyme; Ang II, angiotensin
II; PRA, plasma renin activity; MAP, mean arterial pressure; GFR, glomerular
filtration rate; ERPF, renal plasma flow; RBF, renal blood flow; FF, filtration
fraction; RVR, renal vascular resistance; UNaV, urinary sodium excretion.
FF increased strikingly in men and showed a blunted
increase in women. There were no differences in the
response of UNaV between the two groups.
Impact of plasma 17b-estradiol concentrations
Eight women exhibited 17b-estradiol levels greater
than 300 pmol/liter, and nine had plasma levels less than
100 pmol/liter. The baseline characteristics of these
groups can be found in Table 3. Estrogen status appeared
to influence aldosterone and PRA, MAP, ERPF, and
FF. We were unable to detect any significant difference
between the two groups in the renal hemodynamic re-
sponse to Ang II infusion, although there may have been
a trend toward augmented declines in ERPF in the low
Fig. 1. Change in the glomerular filtration rate (A; DGFR), renal
estrogen state (P 5 0.08; Fig. 2).plasma flow (B; DERPF) and filtration fraction (C; DFF) in response
to angiotensin (Ang) II infusion at 0.5 ng/kg/min (Inf 1), 1.5 ng/kg/min Using correlation coefficients, however, the ERPF re-
(Inf 2), 2.5 ng/kg/min (Inf 3), and at recovery in men ( ) and women sponse to Ang II was significantly correlated with plasma
( ). *P , 0.05 vs. response in men.
17b-estradiol concentrations. As plasma levels increased,
the response to Ang II was blunted. No relationship was
detectable between plasma levels and the GFR response.
response to Ang II infusion, both groups exhibited equiv- There was a significant relationship between the aldoste-
alent small magnitude increases in arterial pressure that rone response to Ang II infusion and plasma 17b-estra-
were statistically significant when compared with base- diol concentrations, with increased plasma levels blunt-
line. As can be seen from Figure 1, there was a significant ing the response (Fig. 3).
decline in ERPF, which was equivalent in both groups.
The response of GFR differed between groups, with men
DISCUSSIONresponding to Ang II infusion by maintaining GFR and
In this study, we examined the baseline componentswomen experiencing a significant decline in GFR that
of the RAS and renal and peripheral responses to Angparalleled the fall in ERPF and that was especially evi-
II in young healthy men and women. The rationale fordent at the smallest infusion rate of Ang II. The GFR
did not return to baseline until the recovery period. The this study was twofold. First, significant gender differ-
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Fig. 2. Change in the glomerular filtration rate (A; DGFR), renal
plasma flow (B; DERPF) and filtration fraction (C; DFF) in response
to Ang II infusion at 0.5 ng/kg/min (Inf 1), 1.5 ng/kg/min (Inf 2), 2.5
ng/kg/min (Inf 3), and at recovery in women with plasma 17b-estradiol
concentrations .300 pmol/liter ( ) and women with plasma 17b-estra-
diol concentrations ,100 pmol/liter (j). *P , 0.05 vs. response in
women with high plasma 17b-estradiol concentrations.
Fig. 3. Relationship between 17b-estradiol plasma concentrations and
change in renal plasma flow (A; DERPF; P 5 0.03, r 5 0.39), glomerular
filtration rate (B; DGFR; P 5 0.77, r 5 0.05), and aldosterone (C;
DAldosterone; P 5 0.008, r 5 0.49), in response to angiotensin (Ang)
II infusion (1.5 ng/kg/min).
ences exist in the progression of renal disease between
men and women, and the RAS has been implicated in
disease progression [9–12]. Second, some confusion ex-
ists in the literature regarding the activity of the RAS discerned by examining baseline components of the RAS
in women. We hypothesized that if gender-mediated dif- and the hemodynamic response to Ang II.
The key findings in this study are as follows: (a) Atferences in RAS function exist, at least some could be
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baseline, women exhibited significantly lower MAP, but of variation, the GFR and ERPF in women is at least
equal to men after correcting for body surface area.no differences in renal and peripheral hemodynamic
function. (b) No significant differences existed in base- Although plasma estrogen concentrations influenced
RBF, RVR and FF, there appeared to be little impactline components of the RAS except for plasma aldoste-
rone, which was reduced in women. (c) Although both on GFR.
Our results also indicate a gender difference in arterialgroups experienced a similar decline in ERPF in re-
sponse to Ang II infusion, the GFR response differed, pressure. Little information is available on arterial pres-
sure in nonhypertensive groups segregated by gender.with men exhibiting maintenance and an augmentation
in FF and women demonstrating a decline in GFR in One such study by Wiinberg et al used 24-hour ambula-
tory blood pressure to determine sex-stratified normalparallel with ERPF and a blunted increase in FF. (d)
Women with plasma 17b-estradiol levels of more than values and found that systolic blood pressure was signifi-
cantly higher in men than in women [20]. In this study,300 pmol/liter exhibited elevations in concentrations of
aldosterone and PRA, decreased ERPF, and increased even in women with elevated estrogens where arterial
pressures tended to be higher, MAP was decreased com-FF and RVR compared with women with plasma 17b-
estradiol levels of less than 100 pmol/liter, suggesting pared with men.
We also noted that aldosterone plasma concentrationsthat higher estrogen plasma concentrations may activate
the intrarenal RAS. (e) There was a significant correla- were significantly lower in women when compared with
men, even though sodium intake was equivalent. Estro-tion between plasma 17b-estradiol levels and the ERPF
response to Ang II, but no correlation between 17b- gen status appeared to influence aldosterone, PRA, and
possibly Ang II, with high levels augmenting these RASestradiol levels and the GFR response.
The baseline renal and peripheral hemodynamic re- components. It is known that estrogen stimulates tran-
scription of the angiotensinogen gene in the liver [1]. Al-sults deserve comment. Few recent studies exist that
compare renal hemodynamic function in men and though the midcycle increase of 17b-estradiol in healthy
women is thought not to be sufficient to increase plasmawomen. In Munich-Wistar rats studied in the conscious,
unanesthetized state, Munger and Baylis [16] noted that angiotensinogen [21], we have clearly shown an impact
of estrogen levels on components of the RAS.females exhibit lower whole-kidney GFR and RPF and
higher RVR. Micropuncture studies performed under an- An important observation from our data was that a
clear gender difference exists in the renal hemodynamicesthesia revealed that single-nephron GFR and plasma
flow were significantly lower, and afferent and efferent response to Ang II. It is known that the highest sensitivity
to the vascular effects of Ang II is found in the kidneyresistances were significantly higher in females, but that
the transglomerular hydraulic pressure difference was and that infusion of low doses that do not affect systemic
blood pressure can induce a substantial constriction ofsimilar in both sexes. When whole-kidney and single-
nephron data for male and female rats were expressed renal vessels [22], resulting in a decline in RBF. GFR
tends to be maintained because of relative changes inper gram kidney weight, no differences remained signifi-
cant. Ovariectomy elevated GFR and plasma flow to a afferent and efferent resistance, with constriction pro-
portionally greater in the efferent arteriole, resulting inpoint intermediate between intact females and males,
such that significant differences were not detectable be- an increased glomerular pressure [23, 24]. Our findings
suggest that female sex predicts a blunted FF responsetween them. Remuzzi et al used the Munich-Wistar rat
model to demonstrate that arterial pressure and whole- to Ang II, possibly signifying lesser increases in intra-
glomerular pressure. It is interesting to note that strikingkidney and single-nephron filtration rates were reduced
in female compared with male rats, differences that per- and equivalent declines in ERPF and RBF and increases
in RVR were noted in both men and women, making itsisted after correction of whole-kidney data for kidney
weight [17]. Plasma flow differences did not reach statisti- difficult to explain our findings on the basis of gender
differences in relative efferent and afferent resistancecal significance when normalized for kidney weight.
Studies in humans are also conflicting. In 1969, Wesson changes. Although our results might suggest an aug-
mented afferent or blunted efferent arteriolar constric-concluded from a compilation of early studies performed
in humans that GFR and RBF were lower in women tive response to Ang II in women, the fact that the
change in ERPF was equivalent in both groups makesthan in men [18]. In a more recent study by Slack and
Wilson, which retrospectively examined inulin and PAH this an unlikely assumption. It is known that Ang II
reduces the ultrafiltration coefficient (Kf), another deter-clearance data from 141 healthy renal transplant donors,
no gender differences were noted in GFR or RBF [19]. minant of GFR, probably due to mesangial cell contrac-
tion. The possibility exists that the Kf response to AngThis study did not control for protein or sodium intake
prior to the study, and there was a large age range. II is more pronounced in women, but because Kf cannot
be measured in human subjects, we are unable to com-In this study, our results from this homogeneous age-
matched group show that although there is a great deal ment on this aspect of the renal microcirculation. Unfor-
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tunately, the results from these experiments in intact ing effect [33] and others not [32]. The possibility exists
that our findings may be unrelated to the RAS, but maykidney function cannot offer any further information
that would clarify the gender differences in the response be indicative of gender differences in counter-regulatory
responses such as renal nitric oxide release. Locally pro-of the renal microcirculation to Ang II. It is important
to note, however, whichever mechanism is operative in duced nitric oxide has been shown to act directly to blunt
the renal vasoconstrictor actions of Ang II by providingwomen, the Ang II-mediated augmentation of FF, and
possibly intraglomerular pressure, appears to be blunted. an opposing vasodilatory stimulus [34]. Renal medullary
endothelial nitric oxide synthase has been shown to beThere is compelling evidence from studies using pharma-
cological blockers of the RAS that the Ang II-mediated significantly augmented by estrogen replacement in oo-
phorectomized female rats [35]. Exhaled nitric oxide hasincrease in intraglomerular pressure is one of the major
mechanisms operative in the progression of renal disease been shown to be elevated in women during the luteal
phase of the menstrual cycle [36], although this is contro-[25–28] and that reductions in glomerular pressure can
ameliorate glomerular injury. Therefore, this phenome- versial [37]. Although activity of this counter-regulatory
system was not evaluated in this study, the fact thatnon may explain in part some of the protection from
renal disease progression noted in women. The mito- estrogen concentrations were not predictive of the GFR
response to Ang II makes it is less likely that estrogen-genic effect of Ang II has also been implicated in disease
progression [13]. In mesangial cells, Ang II increases mediated renal nitric oxide release was responsible for
our GFR findings. The mechanism, therefore, must re-3H-thymidine incorporation, induces hypertrophy, and
stimulates collagen and actin synthesis [29]. Rosenberg main speculative until further study.
In summary, this series of experiments suggests thatand Hostetter studied in vivo intrarenal infusion of Ang
II into rat kidney and noted an increased expression gender predicts the renal hemodynamic response to Ang
II in sodium-replete human subjects. In men, GFR wasof early growth response genes [30]. Any sex-related
differences in the growth-promoting properties of Ang maintained and FF was augmented, whereas in women,
GFR declined in parallel with ERPF, and the rise inII cannot be discerned from our present data, but it is
tempting to speculate that gender differences may also FF was blunted. Whereas estrogen status appeared to
influence both baseline components of the RAS andexist in this aspect of the Ang II response.
Other investigators have noted a gender difference in renal and peripheral hemodynamics, the GFR response
to Ang II could not be explained by this mechanism.the response of ERPF to Ang II infusion. In a recent
study by Hopkins et al [31], gender was a significant Although a complete understanding of sex differences
in Ang II-mediated vasoconstriction of the renal micro-covariate in predicting the renal plasma flow change to
Ang II infusion, with women exhibiting a significantly circulation cannot be discerned from this study of whole-
kidney function, we have provided a possible hypothesisgreater decline in ERPF. We could discern no gender
difference in this parameter in our subjects, although to explain the impact of gender on the progression of
renal disease. Further studies are required both to evalu-the mean age and prestudy preparation were similar.
Hopkins et al did not stratify subjects by phase of the ate other aspects of RAS function in women and to
determine the mechanisms underlying our findings.menstrual cycle, and infusion rates of Ang II differed
from this study, possibly explaining the variations in re-
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